CBSC Announces $375,000 Purchase Order and Launch of Recurring Revenue Program with Noventis Medical

Core Insights - Cardiac Biotech Solutions, Inc. has received an initial purchase order from Noventis Medical for 2,500 MyCardia AT Cardiac Event Monitoring devices, valued at $375,000 USD [1][2] - The order includes immediate shipment of 1,000 devices, with the remaining 1,500 units to be delivered within 90 days [2] - The CEO of CBSC highlighted that this purchase order indicates strong market demand and initiates a sustainable revenue model through device sales and recurring software-driven rental fees [3] - CBSC has established a monthly rental program for ongoing revenue generation, which includes device usage, AWS Cloud-based monitoring software, and patient-facing applications [3][4] - Revenue from the rental program is shared, with CBSC receiving one-third of the monthly fee [4] - The MyCardia AT platform is advancing in global commercialization, with regulatory clearance in the U.S. and submissions in Canada and China [5] - Noventis Medical is a leading distributor of advanced medical technologies in Central America, focusing on innovative healthcare solutions [6] - CBSC provides non-invasive cardiac monitoring products and services, enhancing patient compliance and providing accurate information for physicians [7]